Saturday, July 13, 2024

Health and Pharmaceuticals Central to EU’s Strategic Agenda 2024-2029

Similar articles

Heads of State and Government officially adopted the Strategic Agenda 2024-2029, defining Europe’s priorities for the next European Union (EU) mandate particular focus on health and pharmaceuticals. This adoption is a significant step towards strengthening Europe’s competitiveness on the global stage. The agenda outlines a comprehensive plan aimed at enhancing Europe’s position in various key sectors, with a particular focus on health and pharmaceuticals.

By setting clear objectives and strategies, the agenda marks a crucial moment for Europe’s future, offering a pathway to regain its leadership in life sciences and other critical industries. Commenting on the document, EFPIA Director General Nathalie Moll said, “We are pleased to see EU leaders aligning on the necessity of a new competitiveness deal and the importance of health and pharmaceuticals as key sectors for Europe’s future.

Over the last decades, we have seen an erosion of the R&D base in Europe. After losing its crown to the US as the global leader in pharmaceutical innovation in 2000, Europe is now third behind China in terms of launching new active substances globally. As we begin a new EU mandate, the focus on the competitiveness of the Strategic Agenda allows us to restore Europe’s leadership in life sciences.”

A Unified Commitment to Revitalize the Pharmaceutical Sector

The adoption of the Strategic Agenda 2024-2029 is not just about setting priorities; it represents a unified commitment from EU leaders to tackle the challenges that have hindered Europe’s growth in the pharmaceutical sector. Moll’s comments reflect the broader sentiment within the industry that Europe needs to reclaim its innovative edge. The decline in R&D activities has had far-reaching implications, not just for the pharmaceutical sector but for the overall health and well-being of European citizens.

The Strategic Agenda aims to reverse this trend by fostering a more supportive environment for innovation and development. Earlier this week, EFPIA published a call for a Competitiveness Strategy for European Life Sciences, which includes five pillars designed to help Europe take a new, coherent approach to its life sciences ecosystem. These pillars are intended to address the regulatory burden, attract investments, and increase the region’s attractiveness for launching new medicines.

The Strategic Agenda’s goals align perfectly with these pillars, providing a solid framework for revitalizing Europe’s life sciences sector. By reducing regulatory complexities and creating a more favorable investment climate, the agenda seeks to make Europe a more competitive and dynamic player in the global market. The strategic alignment between EFPIA’s call and the Strategic Agenda underscores the importance of collaboration between industry stakeholders and policymakers.


EFPIA and EU Collaborate on Strategic Agenda for Resilient Health Infrastructure

Over the coming months, EFPIA looks forward to engaging in discussions with EU institutions to refine and implement this vision. Working together, they aim to build a healthier, more competitive, and resilient Europe. This collaboration will be essential in ensuring that Europe can close the gap with other leading regions of the world and reclaim its position as a global leader in pharmaceutical innovation.

In addition to the focus on competitiveness, the Strategic Agenda emphasizes the need for a resilient health infrastructure that can withstand future challenges. This includes not only improving the efficiency and effectiveness of healthcare delivery but also ensuring that the necessary frameworks are in place to support continuous innovation. By fostering a robust and adaptive healthcare ecosystem, Europe can better respond to emerging health threats and provide high-quality care to its population.

You can follow our news on our Telegram and LinkedIn accounts.

The adoption of the Strategic Agenda 2024-2029 is a promising development for Europe’s life sciences sector. By focusing on competitiveness and reducing regulatory burdens, Europe has a clear path to enhancing its global standing and fostering innovation in health and pharmaceuticals. The agenda represents a collective effort to create a more vibrant and resilient European economy, capable of leading in scientific advancements and providing better health outcomes for its citizens.


Resource: European Federation of Pharmaceutical Industries and Associations, June 28, 2024

Subscribe to our newsletter

To be updated with all the latest news, offers and special announcements.

Latest article